Every health tech conference this year will feature a panel titled something like “AI and the Future of Prior Authorization: Toward a Collaborative Care Ecosystem.” The speakers will use the
Why Most Healthcare Brand Strategies Fail the First Time Leadership Gets Tested
A few years ago, I watched a regional nonprofit in community health and wellness come close to imploding. An executive director was let go over financial concerns. Several of her
How AI Can Support Better Mental Health Outcomes — With Humans at the Center
We could all use a little help these days. Americans are lonelier than ever, and more than 1 in 5 now suffers from a mental illness. Demand for support is
Glaucoma Drug Fails Trial, But Bausch + Lomb Sees Opportunity in Another Eye Disease
Bausch + Lomb is dropping plans to develop a drug for glaucoma after the experimental treatment failed a mid-stage clinical trial, but it’s not the end of the road for
Handspring Snags $19M to Fix the “Missing Middle” of Youth Mental Health Care
Pediatric mental health startup Handspring picked up $19 million in Series B funding this week. The company aims to help reshape how children’s mental health care is delivered — mainly
UHC Unveils New Employer-Sponsored Spending Account Benefit
UnitedHealthcare launched a Lifestyle Spending Account on Thursday that aims to give employers a flexible way to fund employees’ health needs. The Lifestyle Spending Account is integrated with UHC Store,
Preventing Medical Errors in Patient Identity Through Data Matching, VBC, and Interoperability Standards
Advancements in interoperability and data sharing have helped more providers share more data than ever before. But these developments come with a new set of challenges hospitals need to solve,
IKS Health Beefs Up Its Tech Stack with $557M Acquisition of TruBridge
IKS Health, a Dallas-based healthcare software company, completed its $557 million acquisition of TruBridge on Thursday. The deal, first announced in April, brings the Mobile, Alabama-based startup — which sells
Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market
An RNA therapy from partners Ionis Pharmaceuticals and AstraZeneca failed a pivotal study as a treatment for a type of cardiomyopathy that can progress to heart failure, dashing hopes of
Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval
A rare autoimmune disease affecting the kidneys has a new FDA approved treatment, a first-in-class Vera Therapeutics drug whose approach of hitting two targets sets it apart from the medicines









